Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2003

Nakamori Mikihito, Fu Xinping, Meng Feng, Jin Aiwu, Tao Lihua, Bast Robert C, Zhang Xiaoliu

Abstract excerpt

PURPOSE AND EXPERIMENTAL DESIGN: Replication-competent herpes simplex virus [HSV (oncolytic HSV)] holds considerable promise for treating malignant solid tumors, although the potency of the virus needs improvement if its full clinical potential is to be realized. Incorporation of membrane fusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chlorocebus aethiops
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycoproteins

Share to Membrane Fusion

Share to Neoplasm Metastasis

Share to Neoplasm Transplantation

Share to Simplexvirus

Share to Vero Cells

Source

Identifiers

PMID: 12855653

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12855653-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.PMID 12855653Read ↗

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerSemantic proximity Read ↗

Rethinking herpes simplex virus: the way to oncolytic agentsSemantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer CellsSemantic proximity Read ↗

Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.Semantic proximity Read ↗

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virusSemantic proximity Read ↗

Glycoprotein targeted therapeutics: a new era of anti‐herpes simplex virus‐1 therapeuticsSemantic proximity Read ↗

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.Semantic proximity Read ↗

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.Semantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53Semantic proximity Read ↗

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.